COMMUNIQUÉS West-GlobeNewswire

CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer

10/09/2024 - 13:00

PRESS RELEASE CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer Highly experienced dealmaker to lead CHARM’s business development and drive strategic value from CHARM’s leading protein-ligand [...]

ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference

10/09/2024 - 13:00

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, [...]

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10/09/2024 - 13:00

WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today [...]

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

10/09/2024 - 13:00

TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to assess additional influenza strains FORT WORTH, Texas, Sept. 10, [...]

Mural Oncology to Host First Virtual Investor Day on September 26, 2024

10/09/2024 - 13:00

Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the potential of new cytokine- [...]

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

10/09/2024 - 13:00

2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT) Favorable safety and tolerability profile with no observations of frequently [...]

Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations

10/09/2024 - 13:00

Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industry to Tonix Tonix is on track to submit an NDA for TNX-102 SL for fibromyalgia in October of 2024 CHATHAM, N.J., [...]

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

10/09/2024 - 13:00

Milestone Results in $8 Million Payment to C4 Therapeutics WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to [...]

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer

10/09/2024 - 13:00

Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewal BOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA [...]

OKYO Pharma Announces Chairman Acquires Shares

10/09/2024 - 13:00

LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye [...]

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

10/09/2024 - 13:00

Entero Therapeutics to integrate applications in planned Phase 3 study of latiglutenase for celiac disease and explore additional uses of technology in clinical trial compliance BOCA RATON, Fla., Sept. 10, 2024 (GLOBE [...]

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

10/09/2024 - 12:57

Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial in Norway Comparing [...]

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

10/09/2024 - 12:35

Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“ [...]

Major shareholder announcement

10/09/2024 - 12:33

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and [...]

Affimed to Present at the Cantor Global Healthcare Conference 2024

10/09/2024 - 12:30

MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight [...]

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

10/09/2024 - 12:30

Mosliciguat, a potential first-in-class and best-in-category inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, is being developed for pulmonary [...]

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

10/09/2024 - 12:30

Mosliciguat is a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability across the spectrum of [...]

Lifera Omics Appoints Prof. Fowzan Alkuraya, a Renowned Genomics Expert as Chief Medical and Genomic Officer

10/09/2024 - 11:48

Lifera, a biopharma company wholly owned by the Public Investment Fund (PIF), launched in 2023, is scaling up its subsidiary Lifera Omics and developing a team of leading Saudi and global talent to fulfil its mission [...]

Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain

10/09/2024 - 10:30

PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Spain, PYLCLARI ® is now available for patients with prostate cancer. PYLCLARI ® (INN: Piflufolastat ( 18 F) [...]